University of Pennsylvania

University of California

Kurt R Brunden

Virginia Man-Yee Lee

John Q Trojanowski

Amos B Smith, Iii

Carlo Ballatore

Kelvin C Luk

Dustin Covell

Xiaozhao Wang

Francesco Piscitelli

Donna Mary Huryn

Adam T Hoye

Anne-Marie L Hogan

James Soper

Killian Oukoloff

Donna M Huym

Sugiyama Shimpei

Onur Atasoylu

Longchuan Huang

Michael James

Virginia MY Lee

The present disclosure provides monoclonal antibodies that bind α-Synuclein. In certain aspects, the antibodies preferentially bind to α-Synuclein fibrils over α-Synuclein monomer. In other aspects, the invention comprises a method of treating α-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting α-Synuclein fibrils using any of the antibodies of the invention.

Monoclonal antibodies against alpha-synuclein fibrils

The present disclosure provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Rx-R8 are defined herein. Also provided are compositions comprising a compound described herein and a pharmaceutically effective excipient, methods of stabilizing microtubules in a patient comprising administering to the patient a microtubule-stabilizing amount of a compound described herein, methods of treating cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein, and methods of treating a neurodegenerative disease in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein. 

Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules

The present disclosure provides monoclonal antibodies that bind &#x3b1;-Synuclein. In certain aspects, the antibodies preferentially bind to &#x3b1;-Synuclein fibrils over &#x3b1;-Synuclein monomer. In other aspects, the invention comprises a method of treating &#x3b1;-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting &#x3b1;-Synuclein fibrils using any of the antibodies of the invention.

Monoclonal antibodies against pathological alpha-synuclein, and methods using same

The present invention is directed to triazolopyrimidine, phenylpyrimidine, pyridopyridazine, and pyridotriazine compounds which are microtubule-stabilizing compounds and their use in the treatment of neurodegenerative disorders, in particular, tauopathies, such as for example, Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration. In addition, the compounds of the invention may be useful for other diseases where tau pathology is a comorbidity or where microtubule function is compromised, for example, schizophrenia, Parkinson's disease (PD), PD with dementia, Lewy body disease with dementia, and amyotrophic lateral sclerosis.

Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies

The present invention is directed to compounds of formula I: wherein A is n is 0, 1, or 2; m is 0 or 1; Ris H or Calkyl and Ris H, Calkyl, Calkaryl, aryl, or heteroaryl; and X is O or NH. Tautomers, enantiomers, and diastereomers, as well as pharmaceutically acceptable salt forms, of compounds of formula I are also within the scope of the invention. Methods of preparing and using the compounds of formula I are also described.  

Cycloalkyl-dione derivatives and methods of their use

The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.

Thromboxane A2 (TP) receptor antagonists

The present invention is directed to carboxylic acid-containing pharmaceutical compounds where the carboxylic acid moieties have been substituted with cycloalkyl-dione derivatives, as well as tautomers and pharmaceutically acceptable salt forms thereof. These bioisosteric replacements improve the compound's ability to effectively cross the blood brain barrier and result in improved pharmacokinetic, toxicological, and/or safety profiles.

Growing community of inventors

Media, PA, United States of America

Kurt R Brunden